Skip to ContentSkip to Navigation
University of Groningenfounded in 1614  -  top 100 university
About us Practical matters How to find us dr. ir. A.M.G. Pasmooij

Publications

Biomarkers for neurodegenerative diseases in regulatory decision-making by the European Medicines Agency

Core outcome domain sets for clinical trials in epidermolysis bullosa — a COSEB protocol to achieve consensus on “what” to measure

Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: A systematic review and meta-analysis of European studies published up to 22 January 2024

Insights from the European Medicines Agency on digital health technology derived endpoints

Learning from European regulator-initiated studies for regulatory decision making

Harmonization of outcomes in epidermolysis bullosa: report of the Core Outcome Sets for Epidermolysis Bullosa (COSEB) kick-off meeting

Patients suffering from dystrophic epidermolysis bullosa are prone to developing autoantibodies against skin proteins: A longitudinal confirmational study

Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa

Access to medicines for rare diseases: A European regulatory roadmap for academia

Community Use of Repurposed Drugs Before and During COVID-19 Pandemic in the Netherlands: An Interrupted Time-Series Analysis